Pesticides & Agrochemicals · Founded 1984 · www.indiapesticideslimited.com · BSE 543311 · NSE IPL · ISIN INE0D6701023
No Notes Added Yet
Business
India Pesticides Ltd. (IPL) is an Indian manufacturer of technical-grade pesticides and active pharmaceutical ingredients (APIs), along with pesticide formulations. The company's core business model involves backward integration for key technicals, enabling them to produce active ingredients which are then used either in their own branded formulations or sold to other agrochemical companies globally (B2B). They also manufacture various formulations (e.g., insecticides, fungicides, herbicides) that are sold to farmers and distributors through their distribution network (B2C/B2B). IPL generates revenue primarily through the sale of these technicals and formulations in both domestic and international markets.
Revenue Mix
IPL operates primarily in two major segments:
Technical-Grade Pesticides: This segment involves the manufacturing of active ingredients (technical products) for various pesticides. IPL produces both proprietary and off-patent technicals. A significant portion of these technicals is exported to various countries.
Pesticide Formulations: This segment involves processing technicals into ready-to-use formulations (e.g., liquids, powders, granules) that are sold under their own brand names. This segment caters primarily to the domestic agricultural market through an established distribution network. While specific percentages can fluctuate, technicals generally contribute a substantial portion of the company's revenue, with formulations being a growing focus.
Industry
The Indian Pesticides & Agrochemicals industry is highly regulated and susceptible to monsoon patterns and agricultural cycles. It is characterized by the presence of both large multinational corporations and numerous domestic players, ranging from large integrated manufacturers to smaller formulators. IPL is positioned as a mid-sized player known for its strong R&D capabilities, particularly in developing and manufacturing technicals, including some niche molecules. The company has a significant export presence for its technical products and is expanding its domestic formulations business to strengthen its market position among Indian farmers.
MOAT
Process Chemistry & R&D: IPL possesses expertise in complex process chemistry, allowing it to develop and commercialize technical-grade pesticides, including some difficult-to-manufacture molecules. This capability leads to cost efficiencies and the ability to introduce new products.
Registrations & Approvals: Obtaining necessary registrations and approvals for technicals and formulations, both domestically and internationally, is a time-consuming and capital-intensive process. IPL's existing portfolio of registrations acts as a significant barrier to entry for new competitors.
Backward Integration: For several key technicals, IPL has backward integration, which provides better control over the supply chain, ensures quality, and can offer a cost advantage over competitors reliant on external sourcing for intermediates.
Established Distribution Network: For its formulations business, IPL has developed a distribution network across India, which is critical for reaching farmers effectively.
Growth Drivers
Increasing Food Demand: Growing global population and changing dietary habits drive demand for higher agricultural output, leading to increased usage of crop protection chemicals.
New Product Development: Continuous R&D leading to the launch of new technicals and formulations, including those with better efficacy or lower environmental impact.
Export Market Expansion: Opportunity to increase market share in the global off-patent technicals market, driven by rising demand from various geographies.
Crop Protection Awareness: Growing awareness among Indian farmers about the benefits of effective crop protection practices to improve yields and quality.
Government Support for Agriculture: Policies and initiatives aimed at boosting agricultural productivity can indirectly drive agrochemical demand.
Risks
Monsoon Dependence: The performance of the Indian agricultural sector, and consequently the demand for agrochemicals, is heavily dependent on the quantity and distribution of the monsoon rains.
Regulatory Risks: Strict environmental regulations, bans on specific pesticides (domestically or internationally), or changes in registration processes can impact product portfolios and profitability.
Raw Material Price Volatility: Fluctuations in the prices of key chemical intermediates and crude oil derivatives can affect manufacturing costs and margins.
Intense Competition: The industry faces strong competition from both established domestic players and multinational companies, leading to potential pricing pressure.
Environmental and Social Scrutiny: Increased public and regulatory scrutiny regarding the environmental impact and safe usage of pesticides.
Foreign Exchange Fluctuations: As a significant exporter, currency volatility can impact revenue realization from international sales and costs of imported raw materials.
Management & Ownership
India Pesticides Ltd. is a promoter-led company, with the Anand Swarup Agarwal family holding a significant ownership stake and playing an active role in management. Mr. Anand Swarup Agarwal serves as the Chairman and Managing Director. The management team generally possesses long-standing experience in the agrochemical sector. The ownership structure typically features a high promoter holding, which is common among Indian family-run businesses.
Outlook
India Pesticides Ltd. is positioned in a growing sector driven by global food security needs and improving agricultural practices. Its strong capabilities in technical manufacturing, coupled with an expanding formulations business, provide a foundation for growth. The company's focus on R&D and backward integration offers competitive advantages. However, the business remains inherently exposed to the cyclicality of monsoons, the volatility of raw material prices, and evolving regulatory landscapes, which are critical factors to monitor. Future performance will largely depend on its ability to consistently launch new products, expand its market reach both domestically and internationally, and effectively navigate sector-specific risks.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 126 | 220 | 229 | 172 | 207 | 275 | 290 | 225 | 266 | 252 |
| Other Income | 4 | 4 | 5 | 3 | 3 | 9 | 5 | 3 | 4 | 4 |
| Total Income | 130 | 224 | 234 | 175 | 211 | 284 | 295 | 229 | 271 | 256 |
| Total Expenditure | 122 | 192 | 195 | 146 | 176 | 230 | 242 | 188 | 225 | 216 |
| Operating Profit | 7 | 32 | 39 | 29 | 35 | 54 | 54 | 41 | 46 | 39 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 5 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 27 | 34 | 23 | 29 | 47 | 47 | 34 | 38 | 31 |
| Provision for Tax | 1 | 7 | 8 | 7 | 7 | 12 | 15 | 11 | 7 | 8 |
| Profit After Tax | 1 | 19 | 26 | 16 | 22 | 35 | 32 | 23 | 31 | 23 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 |
| Profit After Adjustments | 1 | 19 | 26 | 16 | 22 | 35 | 32 | 23 | 31 | 23 |
| Adjusted Earnings Per Share | 0.1 | 1.7 | 2.2 | 1.4 | 1.9 | 3 | 2.7 | 2 | 2.7 | 2 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 649 | 716 | 885 | 680 | 829 | 1057 | 1033 |
| Other Income | 6 | 13 | 13 | 15 | 15 | 21 | 16 |
| Total Income | 655 | 729 | 898 | 696 | 843 | 1079 | 1051 |
| Total Expenditure | 466 | 502 | 688 | 594 | 709 | 884 | 871 |
| Operating Profit | 190 | 227 | 210 | 102 | 134 | 194 | 180 |
| Interest | 3 | 7 | 7 | 4 | 5 | 7 | 8 |
| Depreciation | 6 | 9 | 11 | 15 | 18 | 21 | 22 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 180 | 212 | 192 | 82 | 111 | 166 | 150 |
| Provision for Tax | 45 | 54 | 48 | 22 | 29 | 46 | 41 |
| Profit After Tax | 135 | 158 | 143 | 60 | 82 | 120 | 109 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 135 | 158 | 143 | 60 | 82 | 120 | 109 |
| Adjusted Earnings Per Share | 12 | 13.7 | 12.4 | 5.2 | 7.1 | 10.4 | 9.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 28% | 6% | 10% | 0% |
| Operating Profit CAGR | 45% | -3% | 0% | 0% |
| PAT CAGR | 46% | -6% | -2% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -38% | -24% | -18% | NA% |
| ROE Average | 13% | 10% | 16% | 19% |
| ROCE Average | 17% | 13% | 22% | 25% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 389 | 638 | 773 | 825 | 898 | 1010 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 1 |
| Borrowings | 7 | 4 | 2 | 2 | 2 | 31 |
| Other Non-Current Liabilities | 9 | 17 | 20 | 22 | 23 | 28 |
| Total Current Liabilities | 155 | 187 | 172 | 169 | 263 | 332 |
| Total Liabilities | 561 | 845 | 967 | 1019 | 1187 | 1401 |
| Fixed Assets | 124 | 174 | 248 | 279 | 328 | 388 |
| Other Non-Current Assets | 25 | 68 | 88 | 113 | 88 | 97 |
| Total Current Assets | 412 | 604 | 631 | 626 | 771 | 916 |
| Total Assets | 561 | 845 | 967 | 1019 | 1187 | 1401 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 7 | 3 | 16 | 13 | 10 | 12 |
| Cash Flow from Operating Activities | 83 | 76 | 45 | 115 | 3 | 62 |
| Cash Flow from Investing Activities | -83 | -133 | -24 | -120 | -20 | -83 |
| Cash Flow from Financing Activities | -4 | 71 | -25 | 3 | 19 | 36 |
| Net Cash Inflow / Outflow | -4 | 14 | -4 | -2 | 2 | 15 |
| Closing Cash & Cash Equivalent | 3 | 16 | 13 | 10 | 12 | 27 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 12.03 | 13.72 | 12.43 | 5.22 | 7.13 | 10.4 |
| CEPS(Rs) | 12.58 | 14.45 | 13.42 | 6.53 | 8.71 | 12.25 |
| DPS(Rs) | 0.32 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
| Book NAV/Share(Rs) | 34.84 | 55.39 | 67.11 | 71.61 | 77.99 | 87.67 |
| Core EBITDA Margin(%) | 27.58 | 28.76 | 21.9 | 12.06 | 15.95 | 17.73 |
| EBIT Margin(%) | 27.62 | 29.38 | 22.11 | 12.06 | 15.5 | 17.71 |
| Pre Tax Margin(%) | 27.11 | 28.46 | 21.31 | 11.45 | 14.85 | 16.96 |
| PAT Margin (%) | 20.27 | 21.25 | 15.93 | 8.37 | 10.96 | 12.25 |
| Cash Profit Margin (%) | 21.19 | 22.39 | 17.19 | 10.47 | 13.39 | 14.42 |
| ROA(%) | 23.97 | 22.46 | 15.81 | 6.06 | 7.45 | 9.26 |
| ROE(%) | 34.54 | 30.75 | 20.3 | 7.53 | 9.54 | 12.56 |
| ROCE(%) | 43.68 | 40.75 | 27.82 | 10.7 | 12.96 | 16.76 |
| Receivable days | 117.79 | 113.46 | 103.5 | 127.13 | 141.84 | 131.46 |
| Inventory Days | 38.53 | 51.5 | 74 | 109.97 | 109.67 | 98.89 |
| Payable days | 92.46 | 98.41 | 77.06 | 95.88 | 89.6 | 84.86 |
| PER(x) | 0 | 19.62 | 16.68 | 38.89 | 18.82 | 12.04 |
| Price/Book(x) | 0 | 4.86 | 3.09 | 2.84 | 1.72 | 1.43 |
| Dividend Yield(%) | 0 | 0.28 | 0.36 | 0.37 | 0.56 | 0.6 |
| EV/Net Sales(x) | -0 | 4.2 | 2.63 | 3.3 | 1.81 | 1.35 |
| EV/Core EBITDA(x) | -0.01 | 13.25 | 11.09 | 22.07 | 11.14 | 7.36 |
| Net Sales Growth(%) | 0 | 10.35 | 23.57 | -23.11 | 21.78 | 27.61 |
| EBIT Growth(%) | 0 | 19.11 | -8.99 | -56.4 | 34.07 | 49.08 |
| PAT Growth(%) | 0 | 17.41 | -9.31 | -57.99 | 36.58 | 45.8 |
| EPS Growth(%) | 0 | 13.98 | -9.35 | -57.99 | 36.58 | 45.76 |
| Debt/Equity(x) | 0.08 | 0.02 | 0 | 0.02 | 0.06 | 0.11 |
| Current Ratio(x) | 2.65 | 3.23 | 3.66 | 3.7 | 2.93 | 2.76 |
| Quick Ratio(x) | 2.2 | 2.48 | 2.35 | 2.47 | 2.01 | 1.9 |
| Interest Cover(x) | 53.43 | 31.87 | 27.8 | 19.79 | 24.01 | 23.44 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.01 | 0.03 | 0.07 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.61 | 63.61 | 63.61 | 63.61 | 63.61 | 63.65 | 63.65 | 63.65 | 63.65 | 63.65 |
| FII | 0.26 | 0.32 | 1.75 | 1.85 | 2.52 | 2.78 | 1.88 | 1.87 | 0.2 | 0.09 |
| DII | 0.04 | 0.05 | 0.06 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 36.09 | 36.02 | 34.58 | 34.54 | 33.86 | 33.56 | 34.45 | 34.47 | 36.14 | 36.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 |
| FII | 0.03 | 0.04 | 0.2 | 0.21 | 0.29 | 0.32 | 0.22 | 0.22 | 0.02 | 0.01 |
| DII | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.16 | 4.15 | 3.98 | 3.98 | 3.9 | 3.86 | 3.97 | 3.97 | 4.16 | 4.17 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +28% | +6% | +10% | — |
| Operating Profit CAGR | +45% | -3% | 0% | — |
| PAT CAGR | +46% | -6% | -2% | — |
| Share Price CAGR | -38% | -24% | -18% | — |
| ROE Average | +13% | +10% | +16% | +19% |
| ROCE Average | +17% | +13% | +22% | +25% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.61 | 63.61 | 63.61 | 63.61 | 63.61 | 63.65 | 63.65 | 63.65 | 63.65 | 63.65 |
| FII | 0.26 | 0.32 | 1.75 | 1.85 | 2.52 | 2.78 | 1.88 | 1.87 | 0.2 | 0.09 |
| DII | 0.04 | 0.05 | 0.06 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 36.09 | 36.02 | 34.58 | 34.54 | 33.86 | 33.56 | 34.45 | 34.47 | 36.14 | 36.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 |
| FII | 0.03 | 0.04 | 0.2 | 0.21 | 0.29 | 0.32 | 0.22 | 0.22 | 0.02 | 0.01 |
| DII | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 4.16 | 4.15 | 3.98 | 3.98 | 3.9 | 3.86 | 3.97 | 3.97 | 4.16 | 4.17 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.